Department of Pharmaceutics, K.B. Institute of Pharmaceutical Education and Research , Kadi Sarva Vishwavidyalaya, Gandhinagar , India.
Pharm Dev Technol. 2014 Aug;19(5):513-20. doi: 10.3109/10837450.2013.795171. Epub 2013 May 24.
Intravenous polynuclear iron formulations are vital components in the treatment of iron deficiency anemia associated with chronic kidney disease as well as other diseases associated with gastro-intestinal and cardio-vascular system. Intravenous iron preparations consist of iron-carbohydrate nanoparticles with iron-oxyhydroxide as a core covered by carbohydrate shell. These preparations should be very well characterized in terms of their physicochemical properties and pharmacological profile in order to establish safety and efficacy. The present research work was aimed to physicochemically characterize a new generic iron-sucrose preparation (IS-Claris) and establish its equivalency with the reference product (Venofer®). Various analytical techniques including gel permeation chromatography (GPC), mass spectroscopy (MALDI-TOF), absorption spectroscopy, X-ray diffraction analysis (XRD), nuclear magnetic resonance spectroscopy (proton and (13)C NMR), Fourier transform infrared spectroscopy (FTIR) and thermal gravimetric analysis (TGA) were employed. It was observed that the specifications of IS-Claris obtained through these analyses reflect those of Venofer® and hence the two formulations were considered comparable.
静脉注射多核铁制剂是治疗与慢性肾脏病相关的缺铁性贫血以及与胃肠道和心血管系统相关的其他疾病的重要组成部分。静脉注射铁制剂由铁-碳水化合物纳米颗粒组成,其中铁-氢氧化物为核心,碳水化合物外壳覆盖。为了确定安全性和有效性,这些制剂应在理化性质和药理学特征方面进行非常好的表征。本研究旨在对一种新型的通用蔗糖铁制剂(IS-Claris)进行理化表征,并确定其与参比产品(Venofer®)的等效性。各种分析技术,包括凝胶渗透色谱(GPC)、质谱(MALDI-TOF)、吸收光谱、X 射线衍射分析(XRD)、核磁共振光谱(质子和(13)C NMR)、傅里叶变换红外光谱(FTIR)和热重分析(TGA)都被采用。结果观察到,通过这些分析获得的 IS-Claris 规格反映了 Venofer®的规格,因此这两种制剂被认为是可比的。